The Phase 3 program will consist of two randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VX-548 (100 mg first dose, followed by 50 mg every 12 hours) for acute pain after bunionectomy or abdominoplasty. The primary endpoint in both studies...
若VX-548能在后续研究中取得成功,镇痛药市场将迎来大变革。 主要参考资料: 1、https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-548-treatment. 2、《“3亿疼痛患者,4000亿市场”,一...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTHC...
Vertex Advances VX-548 in Acute and Neuropathic Pain July 22, 2022 - VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy ...
Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548). Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigi...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTH...
根据Vertex最新公开资料,一方面在着手拓展VX-548新的适应症--糖尿病周围神经病变(DPN,Phase II,突破性疗法);腰骶神经根病(LSR,Phase II);另一方面Vertex也在积极布局第三代的Nav1.8抑制剂VX-993以及VX973已经开始了临床I期的研究。VX-993/973会在药效和PK等方面进一步改善。在2024年1月份 J.P. MORGAN HEALTH...
- VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - ...
30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain. The Phase 3 program included two randomized, double-blind, placebo-controlled, ...
METHODSAfter establishing the selectivity of VX-548 forNaV1.8inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of th...